Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pluristem Therapeutc (PSTI)

Pluristem Therapeutc (PSTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,595
  • Shares Outstanding, K 15,548
  • Annual Sales, $ 50 K
  • Annual Income, $ -35,310 K
  • 60-Month Beta 1.05
  • Price/Sales 1,027.90
  • Price/Cash Flow N/A
  • Price/Book 2.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.80
  • Number of Estimates 1
  • High Estimate -0.80
  • Low Estimate -0.80
  • Prior Year -0.80
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.53 +3.68%
on 10/10/19
4.59 -20.26%
on 09/17/19
-0.74 (-16.82%)
since 09/13/19
3-Month
3.24 +12.96%
on 08/15/19
6.40 -42.81%
on 07/18/19
-1.96 (-34.82%)
since 07/12/19
52-Week
3.24 +12.96%
on 08/15/19
12.20 -70.00%
on 10/18/18
-8.14 (-68.98%)
since 10/12/18

Most Recent Stories

More News
Critical Limb Ischemia Drug Market 2019 Global Industry Trends, Statistics, Competition Strategies, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2026

The global Critical Limb Ischemia Drug market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.This report focuses on Critical...

CLBS : 2.31 (+8.96%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (+0.55%)
RNUGF : 2.0600 (unch)
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

-- PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantation

PSTI : 3.66 (+0.55%)
Critical Limb Ischemia Drug Market Analysed by Business Growth, Development Factors and Future Trends by 2026

In 2018, the Critical Limb Ischemia Drug Market revenue was around US$ XX Mn and the Market share was XX%, and it will be projected to reach US$ XX Mn and XX% in 2026, with a CAGR XX% during the forecast...

CLBS : 2.31 (+8.96%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (+0.55%)
RNUGF : 2.0600 (unch)
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information relating to its live Key Opinion Leader...

PSTI : 3.66 (+0.55%)
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced the...

PSTI : 3.66 (+0.55%)
BVXV : 5.66 (unch)
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will host a live Key...

PSTI : 3.66 (+0.55%)
Critical Limb Ischemia Drug Market Is Growing At an Exponential Rate in 2019 and Coming Years

The global Critical Limb Ischemia Drug market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2019 to 2026.

CLBS : 2.31 (+8.96%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (+0.55%)
RNUGF : 2.0600 (unch)
Global Critical Limb Ischemia Drug Market Insights, Forecast to 2019 Analysis by Application, Size, Production, Market Share, Consumption, Trends and Forecast 2025

The market size of Critical Limb Ischemia Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will...

CLBS : 2.31 (+8.96%)
CYYNF : 1.1900 (-4.80%)
HEM.VN : 0.035 (+16.67%)
PSTI : 3.66 (+0.55%)
RNUGF : 2.0600 (unch)
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome

-- Data is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop

PSTI : 3.66 (+0.55%)
Pluristem Therapeutics' CEO Issues Shareholders Update

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its...

PSTI : 3.66 (+0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade PSTI with:

Business Summary

PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use,...

See More

Key Turning Points

2nd Resistance Point 3.85
1st Resistance Point 3.75
Last Price 3.66
1st Support Level 3.56
2nd Support Level 3.47

See More

52-Week High 12.20
Fibonacci 61.8% 8.78
Fibonacci 50% 7.72
Fibonacci 38.2% 6.66
Last Price 3.66
52-Week Low 3.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar